Read Research Alzheimer's More' title='Share this by email.' class='social email'>           

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease

The ability of Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1–42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis. Read & Research Alzheimer’s More

Leave a Reply